Scriabin Research Initiative
Welcome to the Scriabin Project
AstraZeneca R&D Boston — Advancing Gastrointestinal Research
The Scriabin Research Initiative represents a dedicated program within AstraZeneca R&D Boston focused on advancing our understanding of gastrointestinal diseases and developing innovative therapeutic strategies. Named in the spirit of creative discovery and scientific harmony, the Scriabin project brings together researchers from multiple disciplines to tackle some of the most challenging problems in digestive health.
Gastrointestinal disorders affect hundreds of millions of people worldwide, from peptic ulcer disease driven by Helicobacter pylori infection to inflammatory bowel conditions that profoundly impact quality of life. AstraZeneca’s Boston R&D center has built deep scientific expertise in this area, building on decades of experience with proton pump inhibitor therapies and H. pylori eradication strategies.
The Scriabin program operates as an integrated research effort spanning basic science, translational medicine, and clinical development, ensuring that laboratory discoveries can be rapidly translated into meaningful therapeutic advances for patients.
Research Focus Areas
- ▸ Helicobacter pylori eradication
- ▸ Proton pump inhibitor optimization
- ▸ Gastric acid-related disorders
- ▸ Gastrointestinal microbiome
- ▸ Mucosal immune response
Scientific Mission
The Scriabin initiative is built on the principle that breakthroughs in gastrointestinal medicine require a deep, mechanistic understanding of how bacterial pathogens interact with host tissues, how the immune system responds to infection, and how pharmacological interventions can most effectively promote healing and long-term remission.
By integrating expertise in microbiology, immunology, pharmacology, and clinical medicine, the Scriabin program aims to develop the next generation of gastrointestinal therapies that move beyond symptom management to address the underlying causes of disease.